SLC5A2 and atrial fibrillation: The salutary effects of SGLT2 inhibitors was consistent irrespective of whether these patients carried a diagnosis of AF at the time of enrollment, with no reported statistical heterogeneity between the effects of empagliflozin and dapagliflozin.